Psychemedics CorpPMD
PMD
Delisted
PMD was delisted on the 16th of December, 2024.
About: Psychemedics Corp is engaged in providing testing services for the detection of drugs of abuse through the analysis of hair samples. The company operates through a single segment of drug testing services which include training for the collection of samples and storage of positive samples for its customers for an agreed-upon fee per unit testing of samples. The testing methods of the company utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. They provide testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples. Geographically it generates the majority of its revenue from the United States.
Employees: 116
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Psychemedics Corporation Announces Reverse and Forward Stock Split
DALLAS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq: PMD) (the “Company”), the world's leading provider of hair testing for drugs of abuse, today announced that, following the approval of the Company's stockholders at its Annual Meeting of Stockholders held on November 25, 2024, the Company's Board of Directors has approved a 1-for-5,000 reverse stock split of its common stock (the “Reverse Stock Split”) followed immediately by a 5,000-for-1 forward stock split of its common stock (the “Forward Stock Split,” and together with the Reverse Stock Split, the “Stock Split”), to be effective at 5:01 p.m. and 5:02 p.m., Eastern Time, respectively, on Tuesday, December 3, 2024. Beginning with the opening of trading on Wednesday, December 4, 2024, the Company's common stock will continue to trade on the Nasdaq Capital Market on a post-Forward Stock Split basis under the existing symbol “PMD”.
Neutral
GlobeNewsWire
1 month ago
Psychemedics Corporation Reports Third Quarter 2024 Financial Results
DALLAS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ending September 30, 2024.
Neutral
GlobeNewsWire
2 months ago
Psychemedics Releases First-Ever Education Insights Report: Uncovering Drug Trends in Educational Institutions Through Hair Testing
DALLAS, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, is excited to announce the release of its first-ever Education Insights Report.
Neutral
GlobeNewsWire
4 months ago
Psychemedics Corporation Reports Second Quarter 2024 Financial Results
DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's leading provider of hair testing for drugs of abuse, today announced financial results for the second quarter ending June 30, 2024.
Neutral
GlobeNewsWire
4 months ago
Psychemedics Corporation's Board of Directors Approves Plan to Terminate Registration of Its Common Stock
DALLAS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq:PMD) (“Psychemedics” or the “Company”) today announced that a Transaction Committee (the “Transaction Committee”) of the Board of Directors of the Company (the “Board”) comprised of independent directors has recommended, and the Board has approved, a plan to cease the registration of the Company's common stock under the federal securities laws following the completion of a proposed reverse stock split and to delist its shares of common stock from trading on the Nasdaq Capital Market. It is expected that this plan would be effectuated in the fall of 2024, assuming the approval of Psychemedics' stockholders at the Company's 2024 Annual Meeting of Stockholders, among other things, as described below.
Neutral
GlobeNewsWire
6 months ago
Psychemedics Unveils Inaugural Insights Report: Revealing Drug Trends Through Hair Testing
DALLAS, June 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, proudly presents its inaugural Insights Report. This groundbreaking report offers a comprehensive analysis of drug trends in the workplace, drawing insights from a vast dataset of hair samples collected and analyzed in 2023.
Neutral
GlobeNewsWire
7 months ago
Psychemedics Corporation Reports First Quarter 2024 Financial Results
DALLAS, May 14, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's leading provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2024.
Neutral
GlobeNewsWire
8 months ago
Psychemedics Corporation Reports 2023 Financial Results
DALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's leading provider of hair testing for drugs of abuse, announced today financial results for the year ended December 31, 2023.
Neutral
GlobeNewsWire
9 months ago
Psychemedics Recognized as a Top 10 Employee Health Testing Services Provider
Dallas, TX, March 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in drug testing using hair analysis, is proud to announce its recognition as one of the Top 10 Employee Health Testing Services Providers for 2024 by ManageHR. This prestigious accolade highlights Psychemedics' commitment to excellence and innovation in the field of employee health testing.
Neutral
GlobeNewsWire
11 months ago
Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas
ACTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, proudly announces the relocation of its corporate headquarters from Acton, Massachusetts, to Dallas, Texas, while reaffirming its unwavering dedication to delivering exceptional service and maintaining the highest standards in hair drug testing.
Charts implemented using Lightweight Charts™